Skip to content

PanACEA

  • Contact us
  • Twitter
  • News
  • About Us
    • Mission
    • History
    • Governance
    • Donors
    • Scientific Network
  • Tuberculosis
    • Impact
    • Treatment
    • Drug development
  • Clinical Studies
    • Trial Design
    • PanACEA Studies
    • Vision for future Studies
  • Capacity Development

ACRO

Posted on May 17, 2013June 22, 2017 by admin
Posted in partners, Uncategorized

Post navigation

← Accelerating the pathway from drug discovery to patient treatment – pioneering advanced development methodologies for new TB drug regimens
Clinical →

Recent Posts

  • PanACEA General Assembly
  • Press Release
  • PanACEA adds SUDOCU and PHENORIF trials to portfolio
  • Maximum tolerated dose of rifampicin identified
  • Dr. Francis Mhimbira
© PanACEA
  • edctp
  • European Union
  • Contact us
  • Twitter